You are here

  • Home
  • Archive
  • Volume 29, Issue Suppl 3
  • 19 A large, multicenter, retrospective study on efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic ovarian cancer (MITO RT1 study)

Article Text

Article menu

Download PDFPDF

Plenary sessions
Plenary 3
IGCS19-0619
19 A large, multicenter, retrospective study on efficacy and safety of stereotactic body radiotherapy (SBRT) in oligometastatic ovarian cancer (MITO RT1 study)
Free
  1. G Macchia1,
  2. R Lazzari2,
  3. N Colombo3,
  4. C Laliscia4,
  5. G Capelli5,
  6. GR D’Agostino6,
  7. F Deodato1,
  8. F Trippa7,
  9. E Ippolito8,
  10. S Ronchi2,
  11. F Pajar4,
  12. M Scorsetti6,
  13. S Cilla9,
  14. R Ingargiola2,
  15. A Huscher10,
  16. AM Cerrotta11,
  17. F Andrei12,
  18. L Vicenzi13,
  19. D Russo14,
  20. S Borghesi15,
  21. E Perrucci16,
  22. S Pignata17,
  23. C Aristei18,
  24. AG Morganti19,
  25. G Scambia20,
  26. V Valentini21,
  27. BA Jereczek-Fossa2 and
  28. G Ferrandina22
  1. 1Fondazione di Ricerca e Cura Giovanni Paolo II, Radiotherapy Unit, Campobasso, Italy
  2. 2IEO European Institute of Oncology- IRCCS, Division of Radiotherapy, Milan, Italy
  3. 3IEO European Institute of Oncology- IRCCS and University of Milan-Bicocca, Division of Medical Gynecologic Oncology, Milan, Italy
  4. 4Division of Radiation Oncology- University of Pisa, Department of Translational Medicine, Pisa, Italy
  5. 5University of Cassino and Southern Lazio, Department of Human Sciences- Society and Health, Cassino, Italy
  6. 6Humanitas Clinical and Research Hospital – IRCSS, Radiotherapy and Radiosurgery, Rozzano Mi, Italy
  7. 7S. Maria Hospital, Radiation Oncology Centre, Terni, Italy
  8. 8Campus Bio-Medico University, Department of Radiation Oncology, Rome, Italy
  9. 9Fondazione di Ricerca e Cura Giovanni Paolo II, Medical Physic Unit, Campobasso, Italy
  10. 10Fondazione Poliambulanza, U.O. di Radioterapia Oncologica “Guido Berlucchi”, Brescia, Italy
  11. 11Fondazione IRCCS Istituto Nazionale dei Tumori, Radiotherapy Unit, Milan, Italy
  12. 12San Raffaele Scientific Institute, Department of Radiation Oncology, Milan, Italy
  13. 13Azienda Ospedaliera Universitaria Ospedali Riuniti, Oncology and Radiotherapy-, Ancona, Italy
  14. 14Ospedale “Vito Fazzi”, Radiotherapy Unit, Lecce, Italy
  15. 15Azienda USL Toscana sud est- San Donato Hospital, Radiotherapy, Arezzo, Italy
  16. 16University of Perugia and Perugia General Hospital, Radiation Oncology Section, Perugia, Italy
  17. 17Istituto Nazionale Tumori di Napoli, Fondazione Pascale IRCCS, Naples, Italy
  18. 18University of Perugia and Perugia General Hospita, Radiation Oncology Section, Perugia, Italy
  19. 19University of Bologna- S. Orsola-Malpighi Hospital, Department of Experimental- Diagnostic and Specialty Medicine – DIMES, Bologna, Italy
  20. 20Fondazione Policlinico Universitario A. Gemelli- IRCCS, UOC Ginecologia Oncologica- Dipartimento per la salute della Donna e del Bambino e della Salute Pubblica, Roma, Italy
  21. 21Fondazione Policlinico Universitario A. Gemelli- IRCCS, UOC di Radioterapia- Dipartimento di Scienze Radiologiche- Radioterapiche ed Ematologiche, Roma, Italy
  22. 22Fondazione Policlinico Universitario A. Gemelli- IRCCS- UOC Ginecologia Oncologica, Dipartimento per la salute della Donna e del Bambino e della Salute Pubblica, Roma, Italy

Abstract

Objectives The aim of this retrospective, multicenter study (MITO RT-01) was to define activity and safety of Stereotactic Body Radiotherapy (SBRT) in a very large, real life dataset of metastatic/persistent/recurrent ovarian cancer (MPR-OC) patients. Clinical and SBRT parameters have been analyzed in order to identify predictors of outcome.

Methods The endpoints of the study were the rate of complete response (CR) to SBRT, and the 24-month actuarial local control (LC) rate on “per lesion” basis. The secondary end-points were acute and late toxicities, and the 24-month actuarial late toxicity free survival. Toxicity was evaluated by RTOG/EORTC and CTC-AE scales, according to center policy. Logistic and Cox regression were used for the uni- and multivariate analysis of factors predicting clinical CR and actuarial outcomes.

Results CR, PR and SD were observed in 291 (65.2%), 106 (23.8%), and 33 (7.4%) lesions. Patient age <60 years, PTV <18 cm3, lymph node disease, and BEDα/β10 >70 Gy were associated with higher chance of CR in the multivariate analysis. With a median follow-up of 22 months (range: 3–120), the 24-month actuarial LC rate was 81.9%. Achievement of CR and total dose >25 Gy were associated with better LC rate in the multivariate analysis. Mild toxicity was experienced in 54 (20.7%) patients. The 24- month late toxicity free survival rate was 95.1%.

Conclusions This study confirms the activity and safety of SBRT in MPR-OC patients and identifies clinical and treatment parameters able to predict CR and LC rate.

https://doi.org/10.1136/ijgc-2019-IGCS.19

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.